Mark Cuban is trying to shake up biosimilar pricing with a version of J&J’s best-selling Stelara drug

Taking stock of the drug industry, from the lab to the medicine chest

November 6, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Gage Skidmore/Wikimedia Commons STAT+ | Mark Cuban is trying to shake up biosimilar pricing with a version of J&J's best-selling Stelara drug The Mark Cuban Cost Plus Drug Company will sell a cheaper version of Stelara, a J&J treatment used for chronic inflammatory and autoimmune conditions. By Ed Silverman and Elaine Chen STAT+ | Trump announces deal with Lilly, Novo to expand access to weight loss drugs, cut prices Novo Nordisk's Wegovy, Eli Lilly's Zepbound to be sold at discounted prices on TrumpRx, covered by Medicare under new Trump deal. By Daniel Payne and Elaine Chen STAT+ | FDA announces next round of priority review vouchers Process speeds up FDA approval for drugs that reflect Trump priorities. Watchdogs say program may hand out political favors more than advance public health By Lizzy Lawrence Mario Tama/Getty Images STAT+ | FDA approves J&J's antipsychotic drug to treat depression Major depressive disorder is the fourth indication for the drug, and could help turn it into a blockbuster for Johnson & Johnson. By Damian Garde

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser